E-cigarette Perceptions among HIV-positive Smokers in a Switching Study
TOBACCO REGULATORY SCIENCE
Authors: Cioe, Patricia A.; Tidey, Jennifer W.; Mercurio, Alana N.; Costantino, Catherine; Kahler, Christopher W.
Abstract
Objectives: Cigarette smoking is highly prevalent among persons with HIV (PWH), which is concerning due to their increased risk of developing smoking-related cancers compared to those without HIV. Smoking cessation rates are substantially lower among PWH compared to the general population and less than half report a goal of total abstinence. Given these factors, a switch to electronic cigarettes (ECs), as a form of tobacco harm reduction, may be a viable approach to decreasing tobacco-related morbidity and mortality in PWH. The US Food and Drug Administration has the authority to implement product standards for cigarettes, including ECs and flavors. Methods: This qualitative study enrolled 19 HIV-positive smokers into an EC switch study. At Week 12, qualitative interviews were conducted to examine EC perceptions and flavor preferences. Results: ECs were viewed as a less harmful, cost-effective method of reducing or eliminating CC smoking, and non-tobacco flavors were an essential part of EC appeal and use. Conclusions: Flavored EC liquid seems to enhance the user experience and may influence the user's ability to make a complete switch. Tobacco harm reduction, as a strategy, will only be effective if current evidence guides tobacco regulatory decisions.
Expression of HIV-1 pathogenesis factor NEF in CD4 T cells impairs antigen-specific B-cell function
EMBO JOURNAL
Authors: Kaw, Sheetal; Ananth, Swetha; Tsopoulidis, Nikolaos; Morath, Katharina; Coban, Bahar M.; Hohenberger, Ralph; Bulut, Olcay C.; Klein, Florian; Stolp, Bettina; Fackler, Oliver T.
Abstract
Failures to produce neutralizing antibodies upon HIV-1 infection result in part from B-cell dysfunction due to unspecific B-cell activation. How HIV-1 affects antigen-specific B-cell functions remains elusive. Using an adoptive transfer mouse model and ex vivo HIV infection of human tonsil tissue, we found that expression of the HIV-1 pathogenesis factor NEF in CD4 T cells undermines their helper function and impairs cognate B-cell functions including mounting of efficient specific IgG responses. NEF interfered with T cell help via a specific protein interaction motif that prevents polarized cytokine secretion at the T-cell-B-cell immune synapse. This interference reduced B-cell activation and proliferation and thus disrupted germinal center formation and affinity maturation. These results identify NEF as a key component for HIV-mediated dysfunction of antigen-specific B cells. Therapeutic targeting of the identified molecular surface in NEF will facilitate host control of HIV infection.